Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.6%

2 terminated out of 36 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

39%

14 trials in Phase 3/4

Results Transparency

29%

8 of 28 completed with results

Key Signals

8 with results93% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (4)
P 1 (9)
P 2 (1)
P 3 (9)
P 4 (5)

Trial Status

Completed28
Recruiting4
Active Not Recruiting2
Terminated2

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT06657456Not ApplicableCompleted

Impact of Phytosterol-Rich Extract on Lipid Profile

NCT06008756Phase 3Active Not Recruiting

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06275724Active Not Recruiting

Specified Drug-use Survey of Leqvio for s.c. Injection.

NCT07519967Not ApplicableCompleted

Efficacy of Lactobacillus Mucosae DPC6426 on Blood-lipids

NCT07491172Phase 1Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07375225RecruitingPrimary

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

NCT06501443Phase 4RecruitingPrimary

LATAM LOWERS LDL-C

NCT06974266Not ApplicableRecruitingPrimary

An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia

NCT07170852Phase 1CompletedPrimary

Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets

NCT01935674Phase 4Completed

Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels

NCT06923956Phase 1CompletedPrimary

Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

NCT04169386Phase 1CompletedPrimary

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

NCT05934292Phase 1CompletedPrimary

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

NCT00653835Phase 4CompletedPrimary

Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

NCT00328523Phase 3CompletedPrimary

TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)

NCT02770131CompletedPrimary

Chart Review of Repatha® in Subjects With Hyperlipidaemia

NCT03510884Phase 3CompletedPrimary

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT04058834Phase 1Completed

A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels

NCT00163163Phase 3CompletedPrimary

Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women

NCT02906124TerminatedPrimary

Study to Evaluate the Safety of Repatha® in Pregnancy

Scroll to load more

Research Network

Activity Timeline